News Conference News ACC 2024 Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI Shelley Wood April 06, 2024
News Conference News ACC 2023 Real-world Primary MR TEER Outcomes Carry a Reminder: Do Better Shelley Wood March 10, 2023
News Conference News ACC 2023 STELLAR, ‘Impressive’ Results With Novel Drug Sotatercept in PAH Shelley Wood March 06, 2023
News Opinion Editor's Corner ACC 2023 What’s Going to Be Hot at ACC/WCC 2023? Shelley Wood February 27, 2023
News Conference News ACC 2022 Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term Shelley Wood April 03, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Conference News ACC 2022 What’s Going to Be Hot at ACC 2022, In Person or Virtual Shelley Wood March 28, 2022
News Conference News ACC 2021 Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients Shelley Wood May 16, 2021
News Conference News ACC 2021 ‘Enormous’ QoL Improvements With Mavacamten in HCM Shelley Wood May 15, 2021
News Daily News ACC 2020 Better QoL After MitraClip Plus Fewer Deaths, HF Hospitalizations: COAPT Shelley Wood March 17, 2020
News Conference News ACC 2019 New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin Shelley Wood March 26, 2019
News Conference News ACC 2019 Final MOMENTUM 3 Results Secure Superiority Claim for HeartMate 3 LVAD Shelley Wood March 22, 2019
News Conference News ACC 2019 COAPT Echo Substudy in HF Patients With Mitral Regurgitation Offers New Answers, and More Questions Shelley Wood March 17, 2019
News Conference News ACC 2019 ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend Shelley Wood March 11, 2019
News Conference News ACC 2018 Newest HeartMate 3 LV Assist Device Slashes Thrombosis, Reoperation Rates in Advanced HF: MOMENTUM 3 Shelley Wood March 16, 2018
News Conference News ACC 2017 My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time Shelley Wood March 23, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017
News Conference News ACC 2016 CABG Beats Medical Therapy in CAD Patients With Severe LV Dysfunction: STICH 10-Year Results Shelley Wood April 08, 2016